Skip to content

META English logo

Main menu
    • About us
      • Vision, mission and values
      • Diversity, equity & inclusion
      • Executive Leadership Team
      • Global Leaders
      • Board of Directors
      • Our leaders
    • Environmental, social & governance
    • Policies & positions
    • Suppliers
    • Media
    • Press releases
    • Women’s Health Accelerator
    • Rahet Bally x Organon
    • Investor relations overview
    • SEC filings
  • Join our team

Contact Us

Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:

Our focus

Our mission is to deliver impactful medicines and solutions for a healthier every day.

Areas of focus

Our three key areas

Our three pillars—women’s health, biosimilars and established medicines — are the foundation for how we strive to achieve our vision to create a better and healthier every day. We work to provide medicines and other products that help address a wide array of conditions and diseases that women and their loved ones face. Our hope is to give people more choice throughout their lives.

Women’s health

We know women need more choices when it comes to their healthcare. Our goal is to design our portfolio to help address her needs and to create a better and healthier every day, for every woman.

We believe that women are the foundation to a healthier world

We are motivated by a woman’s evolving health needs throughout her lifetime. That’s why our intention is to take on some of the issues that matter most to her.

We aim to empower women to make the right health choices for them with an ambition to help women achieve their family goals.

Because we know there is much more to be done, we will listen to her needs to drive our product development decisions.

Biosimilars

We prioritize our patients first through listening, learning and understanding their needs. As the biosimilar landscape changes, so do we – with an unwavering commitment to providing more options for patients.

Bringing important medicines to patients in need

Biosimilars were introduced with the goal of offering patients more treatment options and reducing healthcare costs related to biologics. Through the adoption of biosimilars, it is estimated that the health care system could save $104 billion from 2020 to 2024.

What is a biosimilar?

Before getting into biosimilars, it helps to know about biologics.

Doctors use biologic medicines to treat a range of serious conditions. A lot of medicines that you pick up at your local drug store are made of fairly simple molecules, whereas biologic medicines have extremely complex molecules. They are made from living organisms, like bacteria or yeast.


What are biosimilar medicines?

Biosimilars are a type of biologic medicine. Biosimilars are approved by the FDA as being highly similar to an already approved biologic medicine. Thus the name, biosimilar.

A biosimilar must show that it is has no clinically meaningful differences in safety, purity and potency compared with the reference biologic.


A biosimilar is not a generic.

Some people think a biosimilar is like a generic medicine. As with generics, biosimilars are designed to be similar to another medicine.


Learn about biosimilars myths & facts

Established medicines

Our portfolio of established medicines has a long history across a range of therapeutic areas.

Providing a range of medicines across diseases and conditions

Our established brands include well-known products across a range of therapeutic areas like respiratory, cardiovascular, dermatology, non-opioid pain and more.

META English logo

Company

  • About us
  • Our leaders
  • Environmental, social & governance

Resources

  • Patient resources
  • Investor relations
  • Media

Contact us

  • Contact Us
  • Contact information
  • Global locations
  • Forward-Looking Statement
  • cookie policy
  • Privacy
  • Terms of Use
  • Sitemap
© 2025 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies.

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept